Amplyx Pharmaceuticals, Inc.

Pfizer Acquires Amplyx Pharmaceuticals to Advance Novel Antifungal Development

3 months ago

• Pfizer has acquired Amplyx Pharmaceuticals, gaining rights to fosmanogepix, a novel Phase 2 antifungal compound that could address drug-resistant fungal infections with mortality rates of 30-80%. • The acquisition strengthens Pfizer's anti-infectives portfolio with fosmanogepix being the potential first new antifungal drug class in 20 years, offering both IV and oral formulations. • The deal builds on Pfizer's initial equity investment from December 2019 and includes Amplyx's early-stage pipeline of antiviral and antifungal therapies.

Basilea's Fosmanogepix Enters Phase 3 for Invasive Candidiasis Treatment

8 months ago

• Basilea Pharmaceutica has initiated a Phase 3 trial (FAST-IC) to assess fosmanogepix for treating candidemia and invasive candidiasis in adults. • Fosmanogepix, a first-in-class antifungal, inhibits the fungal enzyme Gwt1, crucial for cell wall integrity and evading host defenses. • The global, double-blind FAST-IC trial compares intravenous fosmanogepix to intravenous caspofungin, a standard-of-care treatment, in approximately 450 patients. • Fosmanogepix has shown activity against multi-drug-resistant Candida strains and difficult-to-treat molds, offering a potential new treatment option.